Show simple item record

dc.contributor.authorStewart, Trina
dc.date.accessioned2012-12-17
dc.date.accessioned2014-04-14T23:33:18Z
dc.date.accessioned2017-03-02T00:01:17Z
dc.date.available2017-03-02T00:01:17Z
dc.date.issued2004
dc.date.modified2014-04-14T23:33:18Z
dc.identifier.issn0264-410X
dc.identifier.doi10.1016/j.vaccine.2004.03.026
dc.identifier.urihttp://hdl.handle.net/10072/58375
dc.description.abstractHumanPapillomavirus type 16 (HPV16) E6 and E7 oncoproteins are associated with cervical cancer development and progression and can therefore be used as target antigens for cancer immunotherapy. In this study we evaluated the immunogenicity in mice, of different vaccine formulations using recombinant HPV16 derived E6E7 or E7GST fusion proteins. When co-administered with ISCOMATRIXTM adjuvant, these E6E7 proteins consistently induced E7 specific CTL, in vivo tumor protection, antibody and DTH responses. ISCOMATRIX adjuvant has been developed for use in the formulation of novel human vaccines and has been evaluated for safety and toxicity in human trials. A formulation containing aluminum hydroxide (Al(OH)3) gave a lesser degree of E7 specific antibody, and no local E7 specific CTL response but similar DTH and tumor protection. These findings demonstrate the potential of ISCOMATRIX adjuvant to stimulate both cellular and humoral immune responses to endogenously processed target antigens, and hence is the preferred adjuvant when CTL responses are desirable.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.publisherElsevier Ltd
dc.publisher.placeUK
dc.relation.ispartofpagefrom3738
dc.relation.ispartofpageto3743
dc.relation.ispartofjournalVaccine
dc.relation.ispartofvolume22
dc.subject.fieldofresearchCancer Therapy (excl. Chemotherapy and Radiation Therapy)
dc.subject.fieldofresearchBiological Sciences
dc.subject.fieldofresearchAgricultural and Veterinary Sciences
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchcode111204
dc.subject.fieldofresearchcode06
dc.subject.fieldofresearchcode07
dc.subject.fieldofresearchcode11
dc.titleISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codec1x
gro.facultyGriffith Health Faculty
gro.date.issued2004
gro.hasfulltextNo Full Text
gro.griffith.authorStewart, Trina


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record